Kite Pharma, Bluebird Bio Team Up To Fight HPV
Biotechs Kite Pharma (KITE) and Bluebird Bio (BLUE) announced Monday that they’re collaborating on a new treatment for human papillomavirus (HPV), sending both stocks rising. The two companies plan to combine Kite’s expertise with T cell receptors (TCRs), components of cells that regulate the immune response, with Bluebird’s capabilities in gene editing and lentiviruses (harmless viruses that deliver gene therapies). They’re targeting HPV type 16,